Toronto Dominion Bank Makes New Investment in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Toronto Dominion Bank purchased a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 510,600 shares of the company's stock, valued at approximately $6,760,000.

A number of other large investors also recently modified their holdings of the company. Blue Trust Inc. increased its holdings in Takeda Pharmaceutical by 27.0% during the 4th quarter. Blue Trust Inc. now owns 14,430 shares of the company's stock worth $205,000 after purchasing an additional 3,071 shares during the last quarter. Highland Capital Management LLC boosted its position in Takeda Pharmaceutical by 9.8% during the 4th quarter. Highland Capital Management LLC now owns 67,700 shares of the company's stock worth $896,000 after acquiring an additional 6,050 shares during the period. First Affirmative Financial Network raised its stake in shares of Takeda Pharmaceutical by 29.8% in the 4th quarter. First Affirmative Financial Network now owns 20,602 shares of the company's stock worth $273,000 after buying an additional 4,736 shares in the last quarter. SYM FINANCIAL Corp bought a new stake in shares of Takeda Pharmaceutical in the 4th quarter worth $140,000. Finally, Five Oceans Advisors raised its stake in shares of Takeda Pharmaceutical by 22.2% in the 4th quarter. Five Oceans Advisors now owns 18,502 shares of the company's stock worth $245,000 after buying an additional 3,364 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 1.4%

TAK stock traded up $0.21 during mid-day trading on Friday, hitting $15.01. The stock had a trading volume of 1,725,292 shares, compared to its average volume of 1,938,305. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.43. The company has a fifty day moving average of $14.66 and a 200 day moving average of $14.05. The stock has a market capitalization of $47.76 billion, a price-to-earnings ratio of 37.53, a PEG ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The company had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. On average, equities analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.